UNIRETIC
LOE ApproachingNDAORALTABLET
Approved
Jun 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UNIRETIC is an oral small-molecule tablet approved in 1997 by UCB Pharma as an NDA product. The specific mechanism of action and indications are not publicly detailed in available data. This product represents a legacy oral formulation in a mature therapeutic area.
LOE Approaching
With LOE approaching and no current Part D spending data, the brand is entering a critical transition phase; team size is likely scaling or consolidating in preparation for generic competition.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on UNIRETIC offers exposure to lifecycle management and generic defense strategies during a critical business transition. Career growth may be limited by the product's declining phase, but expertise in LOE mitigation is valuable across the portfolio.
Brand ManagerField Sales Representative
Worked on UNIRETIC at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.